Clinical trial · Interventional
The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.
Investigation to Reveal the Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population: COVID-19 Protection and Vaccine Safety (REAL-V)
NCT05033158CI-TRIAL-00067177REAL-VcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the immune response in the cancer population in Belgium being vaccinated with an approved vaccine types being authorized for use in Belgium. This question needs to be answered to make sure that this vulnerable population is properly protected against possible SARS-CoV-2 infection and that vaccine administration is safe.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Cancer patients
- description
- Level of antibodies against SARS-CoV-2 will be measured in these patients
- interventionNames
- Other: Blood sampling
Primary outcomes (1)
- measure
- Immune response
- timeFrame
- 4 months
- description
- The primary endpoint is the quantification of different anti-SARS-CoV-2 specific IgG antibodies 4 months after (first) vaccine administration. Antibody titers to the full Spike, S1, S2, RBD (receptor binding domain) and N (nucleocapsid) protein of SARS-CoV-2 will be measured quantitatively. For this measurement a multiplex SARS-CoV-2 immunoassay will be used.
Secondary outcomes (4)
- measure
- Duration of the immune response
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 18 years or older * Oncological or hematological malignancy or history of it * Life expectancy \> 3 months * Ability to provide informed consent Exclusion Criteria: * Women who are pregnant or breastfeeding * Immune deficiency not related to cancer or cancer treatment * Allergy (multiple); to be determined by physician
References
Publications (0)
Data not yet available
No reference posted for this study.